尼达尼布在特发性肺纤维化患者中的肝毒性：单中心经验 - Suppr

Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: A single-center experience.

作者信息

Ikeda Satoshi, Sekine Akimasa, Baba Tomohisa, Yamakawa Hideaki, Morita Masato, Kitamura Hideya, Ogura Takashi

机构信息

Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Tomioka-Higashi 6-16-1, Kanazawa-ku, Yokohama 236-0051, Japan.

出版信息

Respir Investig. 2017 Jan;55(1):51-54. doi: 10.1016/j.resinv.2016.08.003. Epub 2016 Sep 16.

DOI:10.1016/j.resinv.2016.08.003

PMID:28012494

Abstract

摘要

相似文献

Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: A single-center experience.

Respir Investig. 2017 Jan;55(1):51-54. doi: 10.1016/j.resinv.2016.08.003. Epub 2016 Sep 16.

Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis.

Sci Rep. 2017 Sep 7;7(1):10811. doi: 10.1038/s41598-017-11321-x.

Safety management of treatment with nintedanib in clinical practice of IPF.

Respir Investig. 2017 Jan;55(1):1. doi: 10.1016/j.resinv.2016.12.001.

Delayed Presentation of Hepatocellular Liver Injury After Nintedanib Administration.

Am J Ther. 2017 Jan/Feb;24(1):e107-e108. doi: 10.1097/MJT.0000000000000464.

Severe hepatotoxicity secondary to nintedanib.

Rev Esp Enferm Dig. 2022 Apr;114(4):244-245. doi: 10.17235/reed.2020.7585/2020.

Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study.

Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(1):74-78. doi: 10.36141/svdld.v36i1.7383. Epub 2019 May 1.

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.

Respir Res. 2015 Sep 24;16:116. doi: 10.1186/s12931-015-0276-5.

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.

Eur Respir J. 2015 May;45(5):1382-92. doi: 10.1183/09031936.00198013. Epub 2014 Dec 10.

Low starting-dosage of nintedanib for the reduction of early termination.

Respir Investig. 2019 May;57(3):282-285. doi: 10.1016/j.resinv.2018.12.010. Epub 2019 Feb 13.

Nintedanib reduced decline in FVC in idiopathic pulmonary fibrosis.

Ann Intern Med. 2014 Oct 21;161(8):JC5. doi: 10.7326/0003-4819-161-8-201410210-02005.

引用本文的文献

Disproportionality Analysis of Hepatotoxic and Gastrointestinal Adverse Events Associated With Nintedanib Using the Japanese Adverse Drug Event Report (JADER) Database.

In Vivo. 2025 Jan-Feb;39(1):396-403. doi: 10.21873/invivo.13841.

Anxiety and depression status in patients with idiopathic pulmonary fibrosis and outcomes of nintedanib treatment: an observational study.

Ann Med. 2024 Dec;56(1):2323097. doi: 10.1080/07853890.2024.2323097. Epub 2024 Apr 6.

Identification of Idiopathic Pulmonary Fibrosis and Prediction of Disease Severity via Machine Learning Analysis of Comprehensive Metabolic Panel and Complete Blood Count Data.

Lung. 2024 Apr;202(2):139-150. doi: 10.1007/s00408-024-00673-7. Epub 2024 Feb 20.

A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Adv Ther. 2023 May;40(5):2038-2050. doi: 10.1007/s12325-023-02454-9. Epub 2023 Mar 16.

Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal.

Pharmaceuticals (Basel). 2022 May 23;15(5):645. doi: 10.3390/ph15050645.

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Cells. 2022 Jan 2;11(1):143. doi: 10.3390/cells11010143.

The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study.

SAGE Open Med. 2021 Jun 6;9:20503121211023357. doi: 10.1177/20503121211023357. eCollection 2021.

Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.

BMC Pulm Med. 2021 May 15;21(1):165. doi: 10.1186/s12890-021-01530-6.

Imrecoxib Inhibits Paraquat-Induced Pulmonary Fibrosis through the NF-B/Snail Signaling Pathway.

Comput Math Methods Med. 2020 Oct 13;2020:6374014. doi: 10.1155/2020/6374014. eCollection 2020.

Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis.

Sci Rep. 2019 Aug 19;9(1):12062. doi: 10.1038/s41598-019-48593-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: A single-center experience.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: A single-center experience.

作者信息

机构信息

出版信息

相似文献

引用本文的文献